Treatment of patients with type 2 diabetes with exenatide once weekly versus oral glucose-lowering medications or insulin glargine: achievement of glycemic and cardiovascular goals

被引：0
|
作者：
Alison R Meloni
Mary Beth DeYoung
Jenny Han
Jennie H Best
Michael Grimm
机构：
[1] Amylin Pharmaceuticals,
[2] LLC,undefined
来源：
Cardiovascular Diabetology | / 12卷
关键词：
Number needed to treat; Absolute benefit; Exenatide; Type 2 diabetes; Diabetes mellitus; ADA treatment guidelines; GLP-1;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Effects of glucose-lowering drugs on cardiovascular outcomes in patients with type 2 diabetes
    Tomlinson, Brian
    Hu, Miao
    Zhang, Yuzhen
    Chan, Paul
    Liu, Zhong-Min
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2016, 12 (11) : 1267 - 1271
  • [22] Personalizing Glucose-Lowering Therapy in Patients with Type 2 Diabetes and Cardiovascular Disease
    Inzucchi, Silvio E.
    ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, 2018, 47 (01) : 137 - +
  • [23] Exenatide extended-release: a once weekly treatment for patients with type 2 diabetes
    Mann, Katherine V.
    Raskin, Philip
    DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY, 2014, 7 : 229 - 239
  • [24] Glycemic control and use of glucose-lowering medications in hospital-admitted type 2 diabetes patients over 80 years
    Ditte Resendal Gotfredsen
    Siri Vinther
    Tonny Studsgaard Petersen
    Rikke Cortes
    Thomas Bo Jensen
    Espen Jimenez-Solem
    Mikkel Bring Christensen
    Scientific Reports, 10
  • [25] DURATION-3: Changes in cardiovascular risk factors in patients with type 2 diabetes after 84 weeks of weekly treatment with exenatide or insulin glargine
    Diamant, M.
    VanGaal, L.
    Stranks, S.
    Guerci, B.
    MacConell, L.
    Chan, M.
    Trautmann, M.
    DIABETES & METABOLISM, 2012, 38 : A101 - A101
  • [26] Glycemic control and use of glucose-lowering medications in hospital-admitted type 2 diabetes patients over 80 years
    Gotfredsen, Ditte Resendal
    Vinther, Siri
    Petersen, Tonny Studsgaard
    Cortes, Rikke
    Jensen, Thomas Bo
    Jimenez-Solem, Espen
    Christensen, Mikkel Bring
    SCIENTIFIC REPORTS, 2020, 10 (01)
  • [27] USING HEALTH OUTCOMES MODELING TO ASSESS THE BENEFIT-RISK PROFILE OF EXENATIDE ONCE-WEEKLY VERSUS INSULIN GLARGINE FOR PATIENTS WITH TYPE-2 DIABETES
    Garrison, L.
    Best, J. H.
    Robertson, J. C.
    Wenten, M.
    Bruhn, D.
    VALUE IN HEALTH, 2011, 14 (03) : A93 - A93
  • [28] Quantifying the effect of exenatide and insulin glargine on postprandial glucose excursions in patients with type 2 diabetes
    Brodows, Robert G.
    Qu, Yongming
    Johns, Don
    Kim, Dennis
    Holcombe, John H.
    CURRENT MEDICAL RESEARCH AND OPINION, 2008, 24 (05) : 1395 - 1397
  • [29] Safety and Efficacy of Once-Weekly Exenatide Compared With Insulin Glargine Titrated to Target in Patients With Type 2 Diabetes Over 84 Weeks
    Diamant, Michaela
    Van Gaal, Luc
    Stranks, Stephen
    Guerci, Bruno
    MacConell, Leigh
    Haber, Harry
    Scism-Bacon, Jamie
    Trautmann, Michael
    DIABETES CARE, 2012, 35 (04) : 683 - 689
  • [30] Impact of concomitant oral glucose-lowering medications on the success of basal insulin titration in insulin-naïve patients with type 2 diabetes: a systematic analysis
    Wollenhaupt, Dominik
    Wolters, Jannik
    Abd El Aziz, Mirna
    Nauck, Michael A.
    BMJ OPEN DIABETES RESEARCH & CARE, 2023, 11 (04)
12345